摘要
程序性死亡受体1(programmed death-1,PD-1)是T细胞表面一类重要的共抑制分子,对免疫反应起负性调节作用。PD-1与其配体程序性死亡受体配体1(programmed death ligand 1,PD-L1)结合可抑制肿瘤组织周围的免疫微环境,导致特异性T细胞活性下调,促使肿瘤细胞逃避免疫监视。PD-1/PD-L1抑制剂可以阻断这一信号通路,并激活抗肿瘤免疫应答,抑制肿瘤细胞的生长。本文就PD-1/PD-L1通路抑制剂在不同消化道肿瘤免疫治疗中的研究进展作一综述。
Programmed cell death-1（PD-1） is an important co-inhibitory molecule expressing on T cell that has negative regulations on immune responses. When PD-1 bound to its ligand programmed cell death-ligand（PD-L1）,PD-1/PD-L1 pathway can restrain the immune microenvironment,leading to the down-regulation of tumor-specific T cell activity,and contribute to tumor cells avoiding the immune surveillance and immune escape. PD-1/PDL1 inhibitors may block its signaling pathway and enhance immune responses, thus inhibiting the growth of tumor cells. In this review,we discuss the therapeutics use of PD-1/PD-L1 monoclonal blocking antibodies in the immunotherapy of digestive system neoplasm.
作者
蒙秋华
田婧
覃斐章
覃杨
董敏
MENG Qiuhua, TIAN Jing, QIN Feizhang, QIN Yang, DONG Min(Department of Pharmacology, School of Pharmacy, Guangxi Medical University, Nanning 530021, Guangxi, China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
2018年第8期942-948,共7页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
国家自然科学基金(81302859)
广西高校科学技术项目(2013YB053)
广西医科大学青年基金(GXMUYSF201212)
广西区高校教育改革项目(2015JGA170)
